Agios Pharmaceuticals Inc. is a biopharmaceutical firm that is committed to deliver scientific leadership in the industry. It works in the field of cellular metabolism to transform the lives of patients that were diagnosed with cancer. The company also helps in developing new medicine and creating innovative solutions to help those who have a subset of orphan genetic metabolic diseases, otherwise known as inborn errors of metabolism (IEM).

Today, Agios Pharmaceuticals Inc. announced the closing of its initial public offering (IPO) of its shares of common stock. The IPO offered 6,772,221 shares valued at US$18 per share piece. Underwriters were given option to purchase 883,333 additional shares valued the same as the public offering price less discounts.

JPMorgan and Goldman Sachs & Co. were appointed as joint bookrunning managers for the IPO. Meanwhile, Cowen and Company, as well as Leerink Swan were appointed to act as co-managers for the public offering.